Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

Accsys Technologies PLC (LON:AXS – Get Free Report) insider Louis Eperjesi bought 21,000 shares of the company’s stock in a ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with ...

The AXS Knowledge Leaders ETF has a unique investment approach, focusing on innovative global companies with strong R&D and ...

Axsome Therapeutics (AXSM) announced that AXS-12 achieved the primary endpoint in the ENCORE Phase 3 trial, demonstrating a statistically ...

Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AXS Tactical Income Fund earns a Low Process Pillar rating. The primary detractor from the rating is the instability of talent across its parent firm. The firm's asset-weighted manager tenure of ...

AXS FTSE Vntr Cptl RetTrckr Fd earns an Above Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical ...